The FDA panel meeting starts Thursday in Maryland. Shaun Noorian won’t be watching from home. The CEO of Houston’s Empower Pharmacy is booking a ticket. He wants to see the room. He knows exactly who will be there.
It’s going to be chaotic.
Scott Brunner runs the industry’s trade group and sees it clearly. “It will be a circus,” he says. “Everybody and their brother is coming.”
Hundreds will jam that small room. Telehealth founders. Longevity influencers. Compounding pharmacists. They are flying in because peptides legalization could unlock a market currently worth an estimated $3 billion. The gray market thrives right now, filling a void where science meets desperation. People want results. They want to heal faster. Sleep better. Lose weight.
But there’s no oversight. No safety checks. Just a sketchy supply chain operating in shadows.
The Science vs. The Snake Oil Debate
These substances sit in a legal limbo. Currently, producing them is only legal for “research purposes.” That loophole has spawned a booming black market.
The drugs themselves aren’t magic, but the buzz is real. Peptides are amino acid chains. Some are legal staples like insulin or GLP-1 drugs. The ones generating heat right now? They go by codes. BPC-157. TB-500.
BPC-157 is touted online for healing tendons and muscles. TB-500 is believed to cut inflammation. Do they actually work? There is little hard data.
“I feel like it will be the Wild West for the first six months at least.” — Michelle Davey, founder of Wheel
Health and Human Services Secretary Robert F. Kennedy disagrees with the skepticism. He told Joe Rogan he’s a “big fan.” He argues that legalization would pull Americans away from contaminated Chinese imports. He claims official channels mean safer dosing.
There’s logic there. Buying injectables from unknown overseas vendors carries risks. Contamination. Wrong doses. You might not even get the drug you paid for.
But legal approval also stamps a government seal on unproven efficacy. That worries the FDA’s technical staff. They recommend against expanded access. The Partnership for Safe Medicines calls these drugs “popular, unproven, dangerous.”
Peter Kolchinsky of RA Capital Management asks the hard question: “Is the FDA going to stand on science… or permit all kinds of snake oil?”
The Compounding Boom
Compounding pharmacies are about to get a second life. A century ago, 75% of prescriptions were made in-house. By the 1970s, that dropped to 1%. Modern medicine preferred mass production.
Now? The pendulum is swinging back.
Hormone therapies. Testosterone. GLP-1s. Compounders filled the gaps when shortages hit. They made custom doses for individual patients. It’s not FDA-approved manufacturing, but it is regulated manufacturing.
Companies like Strive Pharmacy are moving fast. Co-founder Mike Walker is waiting on the green light. “We’d love to make them,” he says. “We are just waiting for the FDA.”
Strive just broke ground on a 350,00-square-foot plant in Arizona. It opens early 2027. Empower Pharmacy operates two 212,00-square-foot facilities in Houston. It has received FDA warning letters over quality concerns, but claims to take every inspection seriously.
The infrastructure is growing. Revelation Pharma is rolling up competitors. Hims & Hers, a telehealth giant valued at $7.6 billion, acquired its own pharmacy last year. They are preparing protocols. Clinical strategies. They hired a Harvard-trained longevity expert to lead peptide therapy efforts.
Who Wins If The FDA Says Yes?
The FDA panel will meet for two days. They will likely recommend allowing compounders to produce at least some of the seven peptides on the docket. Online commentators are already calling it “Peptide Liberation Day.”
If that happens, approval isn’t immediate. The FDA makes the final call. That process takes months. Or longer.
For compounders, this is the lifeline they need. The GLP-1 boom was good, but it attracted lawsuits. Eli Lilly and Novo Nordisk sued compounding pharmacies for making knockoffs. Now that GLP-1 supply chains are stabilizing, compounders are looking for the next wave.
Peptides are it.
Why? No patents.
Traditional pharma companies don’t hold exclusive rights to the peptides under review. This removes the biggest barrier to entry. No one can sue compounders for patent infringement.
“No one can say these medications should be made by traditional pharma companies.” — Shaun Noorian, Empower Pharmacy
This opens the door to non-traditional players. Gyms. Vitamin manufacturers. Wellness influencers.
Jon Lenser, CEO of OpenLoop, notes that his clients—gym chains included—are asking about access. Patients want convenience. If a gym can provide peptides, why not?
Investors are circling too. Jesse Dresser of Frier Levitt says targets are already in talks with private equity firms. The financial stakes are high. Noorian estimates Empower could see “several hundred million dollars” in peptide revenue eventually.
The Supply Chain Nightmare
Cheering for approval is easy. Building the supply chain is hard.
Right now, the active ingredients available are research-grade. They are not permitted in human drugs. Switching to pharmaceutical-grade ingredients requires navigating complex regulations. It requires quality control.
Scott Brunner warns about the dilemma nobody wants to discuss: supply.
If the Administration mandates US-sourced ingredients rather than Chinese ones, delays could stretch into years. Setting up compliant manufacturing lines takes time. Months. Perhaps longer.
The market is too big to ignore, though. Brunner thinks the current GLP-1 experience will look minor compared to what’s coming. The scale of demand for anti-aging and recovery peptides is unmatched.
The FDA panel meets Thursday. The room will be full. The stakes are billions.
Will science win? Or will the market simply demand it anyway?
We’ll see in a few days. Or a few years.
